PDF icon PDF herunterladen
Semin Respir Crit Care Med 2023; 44(01): 075-090
DOI: 10.1055/s-0042-1759567
Review Article

Severity of Illness Scores and Biomarkers for Prognosis of Patients with Coronavirus Disease 2019

Rodrigo Cavallazzi
1   Division of Pulmonary, Critical Care Medicine, and Sleep Disorders, University of Louisville, Norton Healthcare, Louisville, Kentucky
,
James Bradley
1   Division of Pulmonary, Critical Care Medicine, and Sleep Disorders, University of Louisville, Norton Healthcare, Louisville, Kentucky
,
Thomas Chandler
2   Norton Infectious Diseases Institute, Norton Healthcare, Louisville, Kentucky
,
Stephen Furmanek
2   Norton Infectious Diseases Institute, Norton Healthcare, Louisville, Kentucky
,
Julio A. Ramirez
2   Norton Infectious Diseases Institute, Norton Healthcare, Louisville, Kentucky
› Institutsangaben
› Weitere Informationen
   Lizenzen und Reprints
Preview

Abstract

The spectrum of disease severity and the insidiousness of clinical presentation make it difficult to recognize patients with coronavirus disease 2019 (COVID-19) at higher risk of worse outcomes or death when they are seen in the early phases of the disease. There are now well-established risk factors for worse outcomes in patients with COVID-19. These should be factored in when assessing the prognosis of these patients. However, a more precise prognostic assessment in an individual patient may warrant the use of predictive tools. In this manuscript, we conduct a literature review on the severity of illness scores and biomarkers for the prognosis of patients with COVID-19. Several COVID-19-specific scores have been developed since the onset of the pandemic. Some of them are promising and can be integrated into the assessment of these patients. We also found that the well-known pneumonia severity index (PSI) and CURB-65 (confusion, uremia, respiratory rate, BP, age ≥ 65 years) are good predictors of mortality in hospitalized patients with COVID-19. While neither the PSI nor the CURB-65 should be used for the triage of outpatient versus inpatient treatment, they can be integrated by a clinician into the assessment of disease severity and can be used in epidemiological studies to determine the severity of illness in patient populations. Biomarkers also provide valuable prognostic information and, importantly, may depict the main physiological derangements in severe disease. We, however, do not advocate the isolated use of severity of illness scores or biomarkers for decision-making in an individual patient. Instead, we suggest the use of these tools on a case-by-case basis with the goal of enhancing clinician judgment.

Keywords

COVID-19 - PSI - CURB-65 - pneumonia - ARDS - biomarkers


Publikationsverlauf

Artikel online veröffentlicht:
16. Januar 2023

© 2023. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA